NFKB1 and Alzheimer disease: Kim et al. revealed the therapeutic effect of donepezil in its response to LPS- and Aβ-induced neuroinflammation by suppressing AKT/MAPK, NLRP3 inflammasome, and NF-κB/STAT3 signaling in vitro and in vivo, suggesting that donepezil was a therapeutic agent for neuroinflammation-associated diseases such as AD [78].